Skip to main content
. 2021 Jun 24;64(13):9042–9055. doi: 10.1021/acs.jmedchem.1c00158

Figure 4.

Figure 4

(A) In healthy control mice, intracolonic administration of helianorphin-19 (10 μM, 100 μL of bolus) had no significant effect on VMRs to CRD compared with vehicle treatment (healthy + vehicle: N = 7 vs healthy + helianorphin-19: N = 6; non-significant, P > 0.05, 2-way RM ANOVA with Sidak’s multiple-comparison test). (B) In mice with CVH, intracolonic helianorphin-19 (10 μM, 100 μL bolus) significantly reduced VMRs to CRD, particularly at 80 mmHg CRD (CVH + vehicle: N = 13 vs CVH + helianorphin-19: N = 8; *P < 0.05, 2-way RM ANOVA with ***P < 0.001, Sidak’s multiple-comparison test). (C) VMR to CRD data from healthy and CVH mice treated with either vehicle or helianorphin-19 represented as the cumulative area under the curve (cumulative AUC, each dot represents data from an individual mouse in each cohort). Overall, CVH mice treated with a vehicle had significantly greater VMRs to CRD compared with healthy control mice treated with either a vehicle (*P < 0.05) or helianorphin-19 (*P < 0.05). CVH mice treated with helianorphin-19 (10 μM, 100 μL bolus) display significantly reduced VMRs to CRD compared with vehicle-treated CVH mice (*P < 0.05). Analysis based on Kruskal–Wallis test followed by Dunn’s multiple-comparison test.